Drugs / AD-118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07476157 | Apr → May 2026 overdue | heart failure | Addpharma Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07476157 ↗ |
| Route | Oral | “Single-dose oral administration of AD-118 or AD-1181, according to randomized sequence.” NCT07476157 ↗ |